Blood Transfusion in Sickle Cell Disease

Blood Transfusion in Sickle Cell Disease

Blood Transfusion in Sickle Cell Disease

Improving the knowledge of peers and families about blood transfusion in sickle cell disease

Improving the knowledge of peers and families about blood transfusion in sickle cell disease

Jacob Pendergrast, MD, FRCPC

University Health Network Blood Transfusion Service Assistant Professor, University of Toronto

Table of contents

Learning for Life: Blood Transfusion in Sickle Cell Disease

Table of contents

Learning for Life: Blood Transfusion in Sickle Cell Disease

Introduction

Introduction

Blood transfusion is the main treatment option for some individuals with SCD and as such, it becomes important for peers and their families/caregivers to learn more about blood transfusion and support blood donor drives.

Learning for Life: Blood Transfusion in Sickle Cell Disease

Learning for Life: Blood Transfusion in Sickle Cell Disease

Additional Resources on Blood Transfusion in Sickle Cell Disease

Additional Resources on Blood Transfusion in Sickle Cell Disease

Articles

Discover other Patient & Caregivers Articles

Discover other Patient & Caregivers Articles

SCAGO

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY®

The Sickle Cell Awareness Group of Ontario (SCAGO) is pleased with the news of CASGEVY (Exagamglogene Autotemcel) receiving marketing authorization for the treatment of Sickle Cell and Thalassemia disorders in Canada.

SCAGO

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY®

The Sickle Cell Awareness Group of Ontario (SCAGO) is pleased with the news of CASGEVY (Exagamglogene Autotemcel) receiving marketing authorization for the treatment of Sickle Cell and Thalassemia disorders in Canada.

SCAGO

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY®

The Sickle Cell Awareness Group of Ontario (SCAGO) is pleased with the news of CASGEVY (Exagamglogene Autotemcel) receiving marketing authorization for the treatment of Sickle Cell and Thalassemia disorders in Canada.

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

Cover image for short acting opiods article for youth in pain

Youth in Pain

Short-Acting Opioid Analgesics for Pain Management

Cover image for short acting opiods article for youth in pain

Youth in Pain

Short-Acting Opioid Analgesics for Pain Management

Cover image for short acting opiods article for youth in pain

Youth in Pain

Short-Acting Opioid Analgesics for Pain Management

Dr. Robert Klaassen

Pain Management

The Role of Parents & Family Members in sickle cell disease pain management

Dr. Robert Klaassen

Pain Management

The Role of Parents & Family Members in sickle cell disease pain management

Dr. Robert Klaassen

Pain Management

The Role of Parents & Family Members in sickle cell disease pain management

Dr. Julie Beaulac, Ph.D., C. Psych.

Adherence to treatment

Improving care and treatment by utilising informed decision making based on pateint preferences and best practices.

Dr. Julie Beaulac, Ph.D., C. Psych.

Adherence to treatment

Improving care and treatment by utilising informed decision making based on pateint preferences and best practices.

Dr. Julie Beaulac, Ph.D., C. Psych.

Adherence to treatment

Improving care and treatment by utilising informed decision making based on pateint preferences and best practices.

SCAGO

COVID-19 and My Child

Understanding how COVID-19 affects your child with sickle cell disease.

SCAGO

COVID-19 and My Child

Understanding how COVID-19 affects your child with sickle cell disease.

SCAGO

COVID-19 and My Child

Understanding how COVID-19 affects your child with sickle cell disease.

Quick Links

Location

Address: 235-415 Oakdale Rd. North York, ON M3N 1W7

Phone: GTA: 416-745-4267

Email: info@sicklecellanemia.ca

Got a Question?

Contact Us

Want to Support Us?

Donate Now

© SCAGO - All Rights Reserved -Disclaimer - Charitable Registration #: 83332 0872 RR 0001

Quick Links

Location

Address: 235-415 Oakdale Rd.

North York, ON M3N 1W7

Phone: 416-745-4267

Email: info@sicklecellanemia.ca

Got a Question?

Contact Us

Want to Support Us?

Donate Now

© SCAGO - All Rights Reserved -Disclaimer - Charitable Registration #: 83332 0872 RR 0001

Quick Links

SCAGO Online

Location

Address: 235-415 Oakdale Rd. North York, ON M3N 1W7

Phone: 416-745-4267

Email: info@sicklecellanemia.ca

Got a Question?

Contact Us

Want to Support Us?

Donate Now

© SCAGO - All Rights Reserved -Disclaimer - Charitable Registration #: 83332 0872 RR 0001